Nectin Therapeutics Licenses Novel Antibodies to Immunome
Nectin Therapeutics has entered into a global, exclusive license agreement with Immunome Inc. (Nasdaq: IMNM) for antibodies targeting an undisclosed target. The deal allows Immunome exclusive rights to a panel of antibodies, with Nectin receiving an upfront payment and eligibility for milestones and royalties. This agreement enables Nectin to focus on its first-in-class anti-PVR program (NTX1088) and advance novel antibody drug conjugates (ADCs) into clinical development.
Immunome will be responsible for the research, development, manufacturing, and commercialization of products incorporating these antibodies. The company believes that the next generation of transformative ADCs will address novel targets by pairing high-quality antibodies with innovative linker-payload technology.
Nectin Therapeutics ha stipulato un accordo di licenza globale ed esclusivo con Immunome Inc. (Nasdaq: IMNM) per anticorpi che mirano a un target non divulgato. L'accordo consente a Immunome diritti esclusivi su un pannello di anticorpi, con Nectin che riceve un pagamento iniziale e l'idoneità a raggiungere traguardi e royalties. Questo accordo permette a Nectin di concentrarsi sul suo programma di anti-PVR first-in-class (NTX108) e di far avanzare nuovi conjugati di farmaci anticorpali (ADC) nello sviluppo clinico.
Immunome sarà responsabile della ricerca, dello sviluppo, della produzione e della commercializzazione dei prodotti che incorporano questi anticorpi. La società crede che la prossima generazione di ADC trasformativi affronterà nuovi obiettivi abbinando anticorpi di alta qualità con tecnologia innovativa per il linker-carico.
Nectin Therapeutics ha firmado un acuerdo de licencia global y exclusivo con Immunome Inc. (Nasdaq: IMNM) para anticuerpos que apuntan a un objetivo no divulgado. El acuerdo otorga a Immunome derechos exclusivos sobre un panel de anticuerpos, con Nectin recibiendo un pago inicial y elegibilidad para hitos y regalías. Este acuerdo permite a Nectin concentrarse en su programa anti-PVR first-in-class (NTX108) y avanzar nuevos conjugados de fármacos anticuerpos (ADC) al desarrollo clínico.
Immunome será responsable de la investigación, el desarrollo, la fabricación y la comercialización de productos que incorporen estos anticuerpos. La compañía cree que la próxima generación de ADC transformadores abordará nuevos objetivos combinando anticuerpos de alta calidad con tecnología innovadora de enlace-carga.
Nectin Therapeutics는 Immunome Inc. (Nasdaq: IMNM)와 공개되지 않은 타겟을 겨냥한 항체에 대해 전 세계 독점 라이선스 계약을 체결했습니다. 이 계약은 Immunome에게 항체 패널에 대한 독점 권한을 부여하며, Nectin은 선불금을 받고 마일스톤 및 로열티에 대한 자격을 갖게 됩니다. 이 계약은 Nectin이 first-in-class anti-PVR 프로그램 (NTX108)에 집중하고 새로운 항체 약물 접합체 (ADC)를 임상 개발로 진행할 수 있도록 합니다.
Immunome은 이러한 항체를 포함한 제품의 연구, 개발, 제조 및 상업화에 대한 책임을 집니다. 이 회사는 차세대 혁신적인 ADC가 고품질 항체와 혁신적인 링커-페이로드 기술을 결합하여 새로운 표적을 해결할 것이라고 믿고 있습니다.
Nectin Therapeutics a signé un accord de licence exclusif mondial avec Immunome Inc. (Nasdaq: IMNM) pour des anticorps ciblant une cible non divulguée. L'accord permet à Immunome d'avoir des droits exclusifs sur un panel d'anticorps, Nectin recevant un paiement initial et étant éligible à des jalons et des redevances. Cet accord permet à Nectin de se concentrer sur son programme anti-PVR first-in-class (NTX108) et de faire progresser de nouveaux conjugés d'anticorps-médicaments (ADC) vers le développement clinique.
Immunome sera responsable de la recherche, du développement, de la fabrication et de la commercialisation des produits incorporant ces anticorps. La société croit que la prochaine génération d'ADCs transformateurs s'attaquera à de nouvelles cibles en associant des anticorps de haute qualité à une technologie innovante de lien-charge.
Nectin Therapeutics hat einen globalen, exklusiven Lizenzvertrag mit Immunome Inc. (Nasdaq: IMNM) für Antikörper abgeschlossen, die auf ein nicht bekanntgegebenes Ziel abzielen. Der Deal gewährt Immunome exklusive Rechte an einem Antikörperpanel, während Nectin eine Vorauszahlung sowie die Berechtigung zu Meilensteinzahlungen und Tantiemen erhält. Diese Vereinbarung ermöglicht es Nectin, sich auf sein first-in-class anti-PVR Programm (NTX108) zu konzentrieren und neuartige Antikörper-Arzneimittel-Konjugate (ADCs) in die klinische Entwicklung voranzubringen.
Immunome ist verantwortlich für die Forschung, Entwicklung, Herstellung und Vermarktung von Produkten, die diese Antikörper enthalten. Das Unternehmen ist überzeugt, dass die nächste Generation transformierender ADCs neue Ziele erreichen wird, indem hochwertige Antikörper mit innovativer Linker-Last-Technologie kombiniert werden.
- Nectin Therapeutics receives upfront payment and potential future milestones and royalties
- Immunome gains exclusive worldwide rights to antibodies against an undisclosed target
- Agreement allows Nectin to focus on its first-in-class anti-PVR program (NTX1088) and advance novel ADCs
- None.
Insights
This licensing agreement between Nectin Therapeutics and Immunome represents a strategic move in the biotechnology sector, particularly in the field of antibody-based cancer therapies. While the financial terms are not disclosed, such deals typically involve significant upfront payments and potential milestone payments, which could positively impact Nectin's cash position and future revenue streams.
For Immunome (NASDAQ: IMNM), this deal expands their portfolio of potential cancer therapies, which could be viewed favorably by investors. However, the undisclosed nature of the target and the early stage of development add uncertainty to the valuation impact. Investors should monitor future announcements for more details on the potential market size and development timeline.
The agreement's structure, with Immunome taking on development and commercialization responsibilities, suggests a risk transfer from Nectin to Immunome. This could be seen as a positive for Nectin, allowing them to focus resources on their lead program NTX1088, while still maintaining potential upside through milestone payments and royalties.
Overall, while this deal shows promise, its undisclosed nature and early stage limit its immediate impact on either company's valuation. Investors should view this as a long-term strategic move rather than a near-term catalyst.
This licensing agreement focuses on antibodies against an undisclosed target, which adds an element of intrigue to the deal. In the field of oncology, novel targets are highly sought after, especially for antibody-drug conjugates (ADCs), which have shown remarkable efficacy in various cancers.
The involvement of Dr. Clay Siegall, a pioneer in ADC development, as Immunome's CEO, lends credibility to the potential of these antibodies. His statement about 'next generation of transformative antibody drug conjugates' suggests that this undisclosed target could be particularly promising.
From a clinical perspective, the lack of specificity about the target makes it challenging to assess the potential impact on cancer treatment. However, the focus on 'novel targets' and 'innovative linker-payload technology' indicates a potential breakthrough in addressing tumor resistance, a significant challenge in oncology.
Nectin's ongoing clinical study of NTX1088, an anti-PVR program, is worth noting. PVR (CD155) is an emerging target in immuno-oncology and success in this program could validate Nectin's approach and potentially increase the value of the antibodies licensed to Immunome.
While the immediate clinical impact is uncertain, this deal represents a trend towards more targeted, personalized cancer therapies, which could significantly improve patient outcomes in the long term.
This licensing agreement exemplifies the current trend in the biotech industry towards collaborative development and risk-sharing. By out-licensing these antibodies, Nectin Therapeutics is employing a capital-efficient strategy, potentially accelerating the development of multiple assets simultaneously.
For Immunome, this deal aligns with their focus on developing first-in-class and best-in-class targeted cancer therapies. The addition of these novel antibodies to their pipeline could enhance their competitive position in the rapidly evolving ADC market, which is projected to reach
The undisclosed nature of the target is not uncommon in early-stage biotech deals, as companies seek to protect potential competitive advantages. However, it does limit our ability to assess the full potential of this agreement.
Interestingly, this deal highlights the growing importance of antibody quality in ADC development. As Dr. Siegall mentioned, pairing high-quality antibodies with innovative linker-payload technology is important for next-generation ADCs. This suggests that Nectin's antibodies may have unique properties that Immunome finds valuable.
From an industry perspective, this agreement underscores the continued interest in ADCs as a promising modality in oncology. It also demonstrates how smaller biotech companies like Nectin can leverage their research capabilities through strategic partnerships, potentially creating value for both parties involved.
– Exclusive worldwide license agreement for antibodies against undisclosed target
"This agreement allows Nectin to realize value while further pursuing and enabling the focus on our first-in-class anti-PVR program (NTX1088) through its ongoing clinical study in tumor types with high unmet need as well as advance our novel ADCs into clinical development. Immunome's leadership team's track record of developing and commercializing novel ADC therapies makes it an ideal partner to advance these promising assets," said Fabian Tenenbaum, Chief Executive Officer of Nectin Therapeutics.
"Immunome believes the next generation of transformative antibody drug conjugates will address novel targets by pairing high-quality antibodies with innovative linker-payload technology," said Clay Siegall, PhD, President and Chief Executive Officer of Immunome. "We appreciate the work Nectin has done on these antibodies and look forward to advancing them further."
Under the terms of the agreement, Nectin granted Immunome an exclusive, worldwide, all-fields license to monoclonal antibodies that are directed to a single undisclosed target. Immunome will be responsible for the research, development, manufacturing and commercialization of products incorporating these antibodies. Nectin will receive an upfront payment and will be eligible for milestones and royalties.
About Nectin Therapeutics, LTD.
Nectin Therapeutics is a clinical stage biotechnology company devoted to transforming the lives of cancer patients by leveraging unique insights into Nectin pathways to develop the next generation of immune oncology (IO) therapies and antibody drug conjugates (ADCs). The company's differentiated therapies have the potential to set new standards for efficacy and patient response rates across various difficult-to-treat cancers. Nectin's technology addresses major escape mechanisms of current IO therapies through a diverse pipeline of novel monoclonal antibodies and antibody drug conjugates (ADCs). It has a world-class scientific and management team with deep experience in oncology drug development and successful track records in building biotechnology companies and developing innovative therapies. Nectin Therapeutics is a venture-backed, privately held company, funded by aMoon Fund, Peregrine Ventures, IBF, Integra Holdings, the Myeloma Investment Fund (MIF), GIBF and the Cancer Focus Fund.
Nectin Contact:
Fabian Tenenbaum
Chief Executive Officer
info@nectintx.com
+1 201 218-1774
View original content:https://www.prnewswire.com/news-releases/nectin-therapeutics-licenses-novel-antibodies-to-immunome-302206469.html
SOURCE Nectin Therapeutics
FAQ
What is the nature of the agreement between Nectin Therapeutics and Immunome (IMNM)?
What will Immunome (IMNM) be responsible for under this agreement?
What financial terms are included in the agreement between Nectin Therapeutics and Immunome (IMNM)?
How does this agreement benefit Nectin Therapeutics' development pipeline?
